Details of Drug-Metabolizing Enzyme (DME)

General Information of Drug-Metabolizing Enzyme (DME) (ID: DE6OQ3W)

DME Name	Cytochrome P450 1A1 (CYP1A1)
Synonyms	Cytochrome P450 family 1 subfamily A member 1; Hydroperoxy icosatetraenoate dehydratase; Cytochrome P450-C; Cytochrome P450-P1; Cytochrome P450 form 6; CYP1A1; CYPIA1
Gene Name	CYP1A1
UniProt ID	CP1A1_HUMAN
INTEDE ID	DME0006
3D Structure	Download 2D Sequence (FASTA) Download 3D Structure (PDB) Download
Gene ID	1543
EC Number	EC: 1.14.14.1 Oxidoreductase Oxygen paired donor oxidoreductase Flavin/flavoprotein donor oxidoreductase EC: 1.14.14.1
Lineage	Species: Homo sapiens Kingdom: Metazoa Phylum: Chordata Class: Mammalia Order: Primates Family: Hominidae Genus: Homo Species: Homo sapiens
Sequence	MLFPISMSATEFLLASVIFCLVFWVIRASRPQVPKGLKNPPGPWGWPLIGHMLTLGKNPH LALSRMSQQYGDVLQIRIGSTPVVVLSGLDTIRQALVRQGDDFKGRPDLYTFTLISNGQS MSFSPDSGPVWAARRRLAQNGLKSFSIASDPASSTSCYLEEHVSKEAEVLISTLQELMAG PGHFNPYRYVVVSVTNVICAICFGRRYDHNHQELLSLVNLNNNFGEVVGSGNPADFIPIL RYLPNPSLNAFKDLNEKFYSFMQKMVKEHYKTFEKGHIRDITDSLIEHCQEKQLDENANV QLSDEKIINIVLDLFGAGFDTVTTAISWSLMYLVMNPRVQRKIQEELDTVIGRSRRPRLS DRSHLPYMEAFILETFRHSSFVPFTIPHSTTRDTSLKGFYIPKGRCVFVNQWQINHDQKL WVNPSEFLPERFLTPDGAIDKVLSEKVIIFGMGKRKCIGETIARWEVFLFLAILLQRVEF SVPLGVKVDMTPIYGLTMKHACCEHFQMQLRS
Function	This enzyme is involved in the metabolism of various endogenous substrates, including fatty acids, steroid hormones and vitamins. It catalyzes the hydroxylation of carbon-hydrogen bonds and exhibits high catalytic activity for the formation of hydroxyestrogens from estrone (E1) and 17beta-estradiol (E2), namely 2-hydroxy E1 and E2, as well as D-ring hydroxylated E1 and E2 at the C15-alpha and C16- alpha positions. It also displays different regioselectivities for polyunsaturated fatty acids (PUFA) hydroxylation and Catalyzes the epoxidation of double bonds of certain PUFA.
KEGG Pathway	Chemical carcinogenesis (hsa05204 ) Metabolic pathways (hsa01100 ) Metabolism of xenobiotics by cytochrome P450 (hsa00980 ) Ovarian steroidogenesis (hsa04913 ) Retinol metabolism (hsa00830 ) Steroid hormone biosynthesis (hsa00140 ) Tryptophan metabolism (hsa00380 )
Reactome Pathway	PPARA activates gene expression (R-HSA-1989781 ) Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE) (R-HSA-2142816 ) Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET) (R-HSA-2142670 ) Xenobiotics (R-HSA-211981 ) Biosynthesis of protectins (R-HSA-9018681 )

Molecular Interaction Atlas (MIA) of This DME

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This DME

44 Approved Drug(s) Metabolized by This DME

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[1]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[2]
Amodiaquine	DME4RA8	Malaria	1F40-1F45	Approved	[3]
BAY 80-6946	DMLOS5R	Follicular lymphoma	2A80	Approved	[4]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[5]
Chloroquine	DMSI5CB	Malaria	1F40-1F45	Approved	[6]
Clenbuterol	DMCKYZ5	Chronic breathing disorder	7A4Z	Approved	[7]
Clofibrate	DMPC1J7	Dysbetalipoproteinemia	5C80.2	Approved	[8]
Dacarbazine	DMNPZL4	Adenocarcinoma	2D40	Approved	[9]
Daunorubicin	DMQUSBT	Acute monocytic leukemia		Approved	[10]
Debrisoquin	DMC50ME	Hypertension	BA00-BA04	Approved	[11]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[12]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[13]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[14]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[15]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[16]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[17]
Flunarizine	DMZU5JP	Migraine	8A80	Approved	[8]
Flutamide	DMK0O7U	Prostate cancer	2C82.0	Approved	[18]
Fluvastatin	DM4MDJY	Arteriosclerosis	BD40	Approved	[19]
Granisetron	DMIUW25	Malignant glioma	2A00.0	Approved	[20]
Haloperidol	DM96SE0	Delirium		Approved	[21]
Ipriflavone	DM0IO13	Osteoporosis	FB83.0	Approved	[22]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[23]
Melatonin	DMKWFBT	Depression	6A70-6A7Z	Approved	[24]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[25]
Mercaptopurine	DMTM2IK	Acute lymphoblastic leukaemia	2A85	Approved	[26]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[27]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[28]
Perazine	DM2AOTZ	Psychotic disorder	6A20-6A25	Approved	[29]
Prazosin	DMCD9YG	Benign prostatic hyperplasia	GA90	Approved	[30]
Procarbazine	DMIK367	Hodgkin lymphoma	2B30	Approved	[31]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[32]
Raltegravir	DMYURI6	Human immunodeficiency virus infection	1C62	Approved	[33]
Retigabine	DMGNYIH	Behcet disease	4A62	Approved	[34]
Riboflavin	DM8YMWE	Acne vulgaris	ED80	Approved	[35]
Riluzole	DMECBWN	Amyotrophic lateral sclerosis	8B60.0	Approved	[36]
Riociguat	DMXBLMP	Chronic thromboembolic pulmonary hypertension		Approved	[37]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[38]
Testosterone cypionate	DMC1TEV	N. A.	N. A.	Approved	[32]
Theophylline	DMRJFN9	Bronchitis	CA20	Approved	[39]
Toremifene	DMQYUWG	Breast cancer	2C60-2C65	Approved	[40]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[41]
ZOTEPINE	DMF3VXA	Anxiety disorder	6B00-6B0Z	Approved	[42]
------------------------------------------------------------------------------------


⏷ Show the Full List of 44 Approved Drug(s)

7 Clinical Trial Drug(s) Metabolized by This DME

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
5-methoxypsoralen	DME2A8X	Psoriasis vulgaris	EA90	Phase 3	[43]
MK-4827	DMLYGH4	Ovarian cancer	2C73	Phase 3	[44]
AFQ056	DMMHSLC	Fragile X syndrome	LD55	Phase 2/3	[45]
2-Methoxyestradiol	DMGBPME	Pulmonary arterial hypertension	BB01.0	Phase 2	[46]
9-AMINOCAMPTOTHECIN	DMQXYRG	Acquired immune deficiency syndrome	1C62.3	Phase 2	[47]
Famitinib	DMSFWT7	Solid tumour/cancer	2A00-2F9Z	Phase 2	[48]
SALVINORIN A	DMJ3HQY	Cerebral vasospasm	BA85.Z	Phase 1	[49]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 Clinical Trial Drug(s)

2 Discontinued Drug(s) Metabolized by This DME

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Phenacetin	DMRQAM0	Analgesia	MB40.8	Withdrawn from market	[50]
Benzydamine	DMEQL9U	Chemotherapy or radiotherapy-induced mucositis	DA42-DA60	Discontinued in Phase 2	[51]
------------------------------------------------------------------------------------

1 Investigative Drug(s) Metabolized by This DME

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acriflavinium chloride	DMYZJ5B	N. A.	N. A.	Investigative	[52]
------------------------------------------------------------------------------------

Molecular Expression Atlas (MEA) of This DME

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This DME

Disease Name	ICD 11	Studied Tissue	p-value	Fold-Change	Z-score
Acute myelocytic leukaemia	2B33.1	Bone marrow	1.37E-01	-9.49E-02	-3.91E-01
Alopecia	ED70	Skin from scalp	8.44E-02	3.45E-01	2.95E-01
Alzheimer's disease	8A20	Entorhinal cortex	6.83E-06	-1.42E-01	-4.93E-01
Ankylosing spondylitis	FA92.0	Pheripheral blood	7.18E-01	7.18E-03	6.40E-02
Aortic stenosis	BB70	Calcified aortic valve	5.11E-01	-1.37E-01	-3.55E-01
Apnea	7A40	Hyperplastic tonsil	4.19E-01	-2.85E-03	-1.72E-02
Arthropathy	FA00-FA5Z	Peripheral blood	5.24E-01	6.33E-02	3.33E-01
Asthma	CA23	Nasal and bronchial airway	1.94E-01	4.89E-02	5.93E-02
Atopic dermatitis	EA80	Skin	6.65E-03	3.22E-01	5.38E-01
Autism	6A02	Whole blood	1.25E-01	-1.10E-01	-4.94E-01
Autoimmune uveitis	9A96	Peripheral monocyte	6.75E-01	-2.61E-02	-1.86E-01
Autosomal dominant monocytopenia	4B04	Whole blood	3.61E-01	4.78E-02	2.17E-01
Bacterial infection of gingival	1C1H	Gingival tissue	6.86E-05	1.01E-01	4.55E-01
Batten disease	5C56.1	Whole blood	3.47E-01	1.69E-02	1.33E-01
Behcet's disease	4A62	Peripheral blood	5.27E-01	-3.43E-02	-2.24E-01
Bipolar disorder	6A60-6A6Z	Prefrontal cortex	2.16E-01	-9.73E-03	-4.11E-02
Bladder cancer	2C94	Bladder tissue	3.08E-03	-2.68E+00	-2.11E+00
Breast cancer	2C60-2C6Z	Breast tissue	5.28E-09	-1.55E-01	-1.78E-01
Cardioembolic stroke	8B11.20	Whole blood	5.24E-02	2.60E-02	1.93E-01
Cervical cancer	2C77	Cervical tissue	7.17E-01	-1.72E-02	-5.33E-02
Childhood onset rheumatic disease	FA20.Z	Peripheral blood	6.80E-01	3.43E-02	1.05E-01
Chronic hepatitis C	1E51.1	Whole blood	8.24E-01	7.47E-02	2.73E-01
Chronic obstructive pulmonary disease	CA22	Lung tissue	5.56E-03	1.38E-01	4.04E-01
Chronic obstructive pulmonary disease	CA22	Small airway epithelium	6.48E-06	2.92E+00	1.40E+00
Chronic rhinosinusitis	CA0A	Sinus mucosa tissue	1.28E-01	-5.67E-02	-2.90E-01
Colon cancer	2B90	Colon tissue	2.62E-03	-8.29E-02	-1.75E-01
Coronary artery disease	BA80-BA8Z	Peripheral blood	4.81E-01	-8.88E-02	-1.15E-01
Diffuse large B-cell lymphoma	2A81	Tonsil tissue	3.93E-01	-1.05E-01	-2.24E-01
Endometriosis	GA10	Endometrium tissue	1.09E-01	-9.50E-02	-2.41E-01
Familial hypercholesterolemia	5C80.00	Peripheral blood	8.98E-02	1.50E-01	2.10E+00
Familial hypercholesterolemia	5C80.00	Whole blood	7.09E-03	-2.38E-01	-7.72E-01
Gastric cancer	2B72	Gastric tissue	8.75E-02	-6.33E-01	-2.13E+00
Glioblastopma	2A00.00	Nervous tissue	5.48E-47	-3.01E-01	-8.32E-01
Glioma	2A00.0Y-2A00.0Z	Brain stem tissue	9.90E-01	-3.64E-02	-1.18E-01
Glioma	2A00.0Y-2A00.0Z	White matter tissue	2.46E-02	9.11E-02	1.61E-01
Head and neck cancer	2D42	Head and neck tissue	1.33E-03	-1.84E-02	-1.02E-02
HIV-associated neurocognitive impairment	8A2Y-8A2Z	White matter tissue	2.24E-01	-1.24E-01	-5.62E-01
Huntington's disease	8A01.10	Whole blood	3.39E-01	-1.41E-01	-7.19E-01
Idiopathic pulmonary fibrosis	CB03.4	Lung tissue	2.52E-01	-2.19E-01	-2.26E-01
Immunodeficiency	4A00-4A20	Peripheral blood	7.54E-01	7.57E-02	9.05E-01
Influenza	1E30	Whole blood	4.04E-01	2.59E-02	2.94E-01
Interstitial cystitis	GC00.3	Bladder tissue	1.25E-02	-2.09E+00	-2.00E+00
Intracranial aneurysm	8B01.0	Intracranial artery	9.97E-02	-2.81E-01	-7.92E-01
Irritable bowel syndrome	DD91.0	Rectal colon tissue	7.16E-01	5.65E-02	1.66E-01
Ischemic stroke	8B11	Peripheral blood	4.00E-01	1.96E-02	1.29E-01
Juvenile idiopathic arthritis	FA24	Peripheral blood	2.98E-02	8.63E-02	3.41E-01
Lateral sclerosis	8B60.4	Skin	8.86E-01	3.14E-02	8.69E-02
Lateral sclerosis	8B60.4	Cervical spinal cord	1.89E-01	1.53E-01	9.88E-01
Liver cancer	2C12.0	Liver tissue	2.48E-09	-2.66E+00	-2.18E+00
Liver failure	DB99.7-DB99.8	Liver tissue	3.24E-05	-4.16E+00	-3.50E+00
Lung cancer	2C25	Lung tissue	1.99E-02	-3.84E-03	-3.55E-03
Lupus erythematosus	4A40	Whole blood	8.79E-02	-8.23E-02	-1.08E-01
Major depressive disorder	6A70-6A7Z	Hippocampus	9.33E-01	3.62E-02	1.51E-01
Major depressive disorder	6A70-6A7Z	Whole blood	2.61E-01	1.37E-03	5.40E-03
Melanoma	2C30	Skin	8.74E-01	5.66E-02	5.84E-02
Multiple myeloma	2A83.1	Peripheral blood	2.33E-01	1.26E-01	3.83E-01
Multiple myeloma	2A83.1	Bone marrow	2.72E-02	-1.97E-01	-8.12E-01
Multiple sclerosis	8A40	Plasmacytoid dendritic cells	5.01E-01	-1.01E-02	-6.05E-02
Myelodysplastic syndrome	2A36-2A3Z	Bone marrow	8.93E-01	-4.38E-03	-9.40E-03
Myelofibrosis	2A20.2	Whole blood	5.59E-03	1.79E-01	1.05E+00
Myocardial infarction	BA41-BA50	Peripheral blood	1.73E-03	7.35E-01	1.07E+00
Myopathy	8C70.6	Muscle tissue	3.18E-02	-5.95E-01	-5.76E-01
Neonatal sepsis	KA60	Whole blood	3.28E-02	6.59E-02	2.63E-01
Neuroectodermal tumour	2A00.11	Brain stem tissue	1.22E-03	-6.41E-01	-1.80E+00
Non-alcoholic fatty liver disease	DB92	Liver tissue	6.25E-01	-5.57E-01	-5.51E-01
Obesity related type 2 diabetes	5A11	Omental adipose tissue	1.25E-01	1.91E-01	6.80E-01
Olive pollen allergy	CA08.00	Peripheral blood	6.85E-01	-1.63E-01	-2.11E-01
Oral cancer	2B6E	Oral tissue	4.45E-03	-2.74E-01	-2.72E-01
Osteoarthritis	FA00-FA0Z	Synovial tissue	3.84E-02	-9.06E-01	-8.94E-01
Osteoporosis	FB83.1	Bone marrow	7.99E-01	1.82E-01	2.45E-01
Ovarian cancer	2C73	Ovarian tissue	5.71E-01	-1.43E-01	-5.46E-01
Pancreatic cancer	2C10	Pancreas	1.38E-04	-3.36E-01	-1.19E+00
Parkinson's disease	8A00.0	Substantia nigra tissue	7.84E-01	-1.03E-01	-4.48E-01
Pediatric respiratory syncytial virus infection	CA40.11	Peripheral blood	4.30E-01	-5.57E-03	-3.08E-02
Pituitary cancer	2D12	Pituitary tissue	1.55E-02	2.48E-01	7.63E-01
Pituitary gonadotrope tumour	2D12	Pituitary tissue	1.31E-01	1.19E-01	3.91E-01
Polycystic ovary syndrome	5A80.1	Vastus lateralis muscle	8.67E-01	7.63E-03	2.91E-02
Polycythemia vera	2A20.4	Whole blood	2.43E-12	3.21E-01	1.69E+00
Pompe disease	5C51.3	Biceps muscle	6.86E-01	-3.43E-02	-1.84E-01
Preterm birth	KA21.4Z	Myometrium	3.01E-01	-2.66E-02	-1.35E-01
Prostate cancer	2C82	Prostate	3.83E-02	-4.91E-01	-4.02E-01
Psoriasis	EA90	Skin	7.81E-09	-9.88E-01	-6.02E-01
Rectal cancer	2B92	Rectal colon tissue	7.71E-01	-2.82E-02	-1.18E-01
Renal cancer	2C90-2C91	Kidney	8.34E-04	-6.01E-01	-1.73E+00
Retinoblastoma	2D02.2	Uvea	5.40E-02	-2.03E-01	-1.83E+00
Rheumatoid arthritis	FA20	Synovial tissue	3.71E-02	-9.79E-01	-1.13E+00
Rhinovirus infection	CA42.1	Nasal epithelium tissue	6.79E-01	-1.94E-02	-2.31E-02
Schizophrenia	6A20	Prefrontal cortex	2.32E-01	-3.66E-02	-1.30E-01
Schizophrenia	6A20	Superior temporal cortex	6.55E-01	1.27E-02	8.44E-02
Scleroderma	4A42.Z	Whole blood	2.88E-02	-1.27E-01	-9.50E-01
Seizure	8A60-8A6Z	Whole blood	4.82E-01	9.24E-03	3.62E-02
Sensitive skin	EK0Z	Skin	5.77E-01	-2.08E-01	-2.56E-01
Sepsis with septic shock	1G41	Whole blood	2.55E-09	1.64E-01	6.56E-01
Shwachman-Diamond syndrome	3A70.0	Bone marrow	1.86E-01	3.91E-01	8.45E-01
Sickle cell disease	3A51.0-3A51.3	Peripheral blood	4.92E-01	2.74E-01	4.93E-01
Simpson golabi behmel syndrome	LD2C	Adipose tissue	3.01E-01	-5.79E-02	-6.41E-01
Sjogren's syndrome	4A43.2	Salivary gland tissue	4.53E-01	-5.22E-02	-1.69E-01
Skin cancer	2C30-2C3Z	Skin	1.66E-11	-4.25E-01	-2.87E-01
Thrombocythemia	3B63	Whole blood	1.69E-04	2.49E-01	1.39E+00
Thrombocytopenia	3B64	Whole blood	7.49E-01	0.00E+00	0.00E+00
Thyroid cancer	2D10	Thyroid	1.13E-02	4.75E-02	1.99E-01
Tibial muscular dystrophy	8C75	Muscle tissue	2.71E-02	-2.19E-01	-1.44E-01
Tuberous sclerosis complex	LD2D.2	Perituberal tissue	8.45E-01	5.81E-02	2.32E-01
Type 2 diabetes	5A11	Liver tissue	6.63E-01	3.55E-01	4.13E-01
Ureter cancer	2C92	Urothelium	9.34E-01	-1.74E-01	-3.73E-01
Uterine cancer	2C78	Endometrium tissue	2.46E-01	-7.08E-03	-2.10E-02
Vitiligo	ED63.0	Skin	4.32E-01	-5.47E-01	-4.60E-01
------------------------------------------------------------------------------------


⏷ Show the Full List of DME Expression Under 107 Diseases

References

1	Preferred orientations in the binding of 4'-hydroxyacetanilide (acetaminophen) to cytochrome P450 1A1 and 2B1 isoforms as determined by 13C- and 15N-NMR relaxation studies. J Med Chem. 1994 Mar 18;37(6):860-7.
2	A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab Dispos. 2000 Nov;28(11):1303-10.
3	Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J Pharmacol Exp Ther. 2002 Feb;300(2):399-407.
4	FDA label of Copanlisib. The 2020 official website of the U.S. Food and Drug Administration.
5	Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem Res Toxicol. 2003 Mar;16(3):336-49.
6	In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. Drug Metab Dispos. 2003 Jun;31(6):748-54.
7	Beta-adrenergic receptor modulation of the LPS-mediated depression in CYP1A activity in astrocytes. Biochem Pharmacol. 2005 Mar 1;69(5):741-50.
8	Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull. 1996 Nov;19(11):1511-4.
9	Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1. Clin Cancer Res. 1999 Aug;5(8):2192-7.
10	The effect of new lipophilic chelators on the activities of cytosolic reductases and P450 cytochromes involved in the metabolism of anthracycline antibiotics: studies in vitro. Physiol Res. 2004;53(6):683-91.
11	4-Hydroxylation of debrisoquine by human CYP1A1 and its inhibition by quinidine and quinine. J Pharmacol Exp Ther. 2002 Jun;301(3):1025-32.
12	Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
13	Cytochromes P450 in crustacea. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1998 Nov;121(1-3):157-72.
14	Cytochrome P450 isoforms catalyze formation of catechol estrogen quinones that react with DNA. Metabolism. 2007 Jul;56(7):887-94.
15	A common CYP1B1 polymorphism is associated with 2-OHE1/16-OHE1 urinary estrone ratio. Clin Chem Lab Med. 2005;43(7):702-6.
16	Xenobiotic metabolizing and antioxidant enzymes in normal and neoplastic human breast tissue. Eur J Drug Metab Pharmacokinet. 1998 Oct-Dec;23(4):497-500.
17	The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol. Drug Metab Dispos. 2004 Nov;32(11):1209-12.
18	Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J Pharmacol Exp Ther. 2001 Feb;296(2):537-41.
19	Regulation of cytochrome P450 expression by inhibitors of hydroxymethylglutaryl-coenzyme A reductase in primary cultured rat hepatocytes and in rat liver. Drug Metab Dispos. 1996 Nov;24(11):1197-204.
20	CYP1A1 is a major enzyme responsible for the metabolism of granisetron in human liver microsomes. Curr Drug Metab. 2005 Oct;6(5):469-80.
21	In vitro characterization of the metabolism of haloperidol using recombinant cytochrome p450 enzymes and human liver microsomes. Drug Metab Dispos. 2001 Dec;29(12):1638-43.
22	Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous ipriflavone in rats. J Pharm Pharmacol. 2006 Apr;58(4):449-57.
23	Increasing the intracellular availability of all-trans retinoic acid in neuroblastoma cells. Br J Cancer. 2005 Feb 28;92(4):696-704.
24	Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos. 2005 Apr;33(4):489-94.
25	Rat hepatic CYP1A1 and CYP1A2 induction by menadione. Toxicol Lett. 2005 Feb 15;155(2):253-8.
26	Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy. Curr Drug Metab. 2007 Aug;8(6):554-62.
27	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
28	The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
29	The metabolism of the piperazine-type phenothiazine neuroleptic perazine by the human cytochrome P-450 isoenzymes. Eur Neuropsychopharmacol. 2004 May;14(3):199-208.
30	Role of adrenoceptor-linked signaling pathways in the regulation of CYP1A1 gene expression. Biochem Pharmacol. 2005 Jan 15;69(2):277-87.
31	In vitro and in vivo evidence for the formation of methyl radical from procarbazine: a spin-trapping study. Carcinogenesis. 1992 May;13(5):799-805.
32	Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity. Pharmacogenetics. 2000 Aug;10(6):519-30.
33	Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients. Ther Drug Monit. 2010 Dec;32(6):782-6.
34	Retigabine N-glucuronidation and its potential role in enterohepatic circulation. Drug Metab Dispos. 1999 May;27(5):605-12.
35	Disruption of endogenous regulator homeostasis underlies the mechanism of rat CYP1A1 mRNA induction by metyrapone. Biochem J. 1998 Apr 1;331 ( Pt 1):273-81.
36	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
37	Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. P T. 2014 Nov;39(11):749-58.
38	Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos. 2002 Aug;30(8):869-74.
39	Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J Pharmacol Exp Ther. 1993 Apr;265(1):401-7.
40	Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes. Biochem Pharmacol. 1994 May 18;47(10):1883-95.
41	Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes. Drug Metab Dispos. 1999 Nov;27(11):1260-6.
42	Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, an antipsychotic drug, in human liver microsomes. Xenobiotica. 1999 Mar;29(3):217-29.
43	Cytochrome P450 CYP1B1 interacts with 8-methoxypsoralen (8-MOP) and influences psoralen-ultraviolet A (PUVA) sensitivity. PLoS One. 2013 Sep 23;8(9):e75494.
44	Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J Med Chem. 2009 Nov 26;52(22):7170-85.
45	Methods to Assess Pulmonary Metabolism.
46	Role of 2-methoxyestradiol, an Endogenous Estrogen Metabolite, in Health and Disease. Mini Rev Med Chem. 2015;15(5):427-38.
47	Cytochrome P450 3A-mediated metabolism of the topoisomerase I inhibitor 9-aminocamptothecin: impact on cancer therapy. Int J Oncol. 2014 Aug;45(2):877-86.
48	Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
49	Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen. Eur J Pharm Biopharm. 2009 Jun;72(2):471-7.
50	Identification of CYP3A4 as the enzyme involved in the mono-N-dealkylation of disopyramide enantiomers in humans. Drug Metab Dispos. 2000 Aug;28(8):937-44.
51	In vitro evaluation of potential in vivo probes for human flavin-containing monooxygenase (FMO): metabolism of benzydamine and caffeine by FMO and P450 isoforms. Br J Clin Pharmacol. 2000 Oct;50(4):311-4.
52	Activation of the antitumor agent aminoflavone (NSC 686288) is mediated by induction of tumor cell cytochrome P450 1A1/1A2. Mol Pharmacol. 2002 Jul;62(1):143-53.